Skip to main content
SpringerLink
Log in

Mitoxantrone monotherapy appears to be an alternative to combination chemotherapy in patients with high-risk metastatic breast cancer

  • Clinical study
  • Published:
Inpharma Weekly

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mitoxantrone monotherapy appears to be an alternative to combination chemotherapy in patients with high-risk metastatic breast cancer. Inpharma Wkly. 1235, 10 (2000). https://doi.org/10.2165/00128413-200012350-00023

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-200012350-00023

Keywords

Search

Navigation